Balanced news tone
News Sentiment
TLSA sentiment intelligence
Tiziana Life Sciences Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
59
Balanced news tone
50 relevant articles
Price is moving more forcefully than the current news tone suggests.
81/100 classification confidence.
directly relevant articles
high-authority source matches
-13.0% over one week, -7.8% over four weeks, trend inactive, and near fair-value range.
Price to book forward of Tiziana Life Sciences Ltd – NASDAQ:TLSA
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
81/100 classification
One-week reaction
-13.0%
Price reacting lower
Trend fit
Trend inactive
-7.8% over four weeks
Fair value
-3.4%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
19
Neutral
29
Negative
2
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 07:00
- Source
- Market source
TradingView
Direct company coverage
Price to book forward of Tiziana Life Sciences Ltd – NASDAQ:TLSA
This page from TradingView displays the "Price to book forward" metric for Tiziana Life Sciences Ltd (NASDAQ: TLSA). The content is primarily a data placeholder, indicating the financial metric for the company, and is surrounded by standard website navigation and footers. The act
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 19:40
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Tiziana Life Sciences Ltd – NASDAQ:TLSA
This article provides financial information for Tiziana Life Sciences Ltd (NASDAQ: TLSA), specifically focusing on its price to sales forward metric. It lists the company's stock exchange as Nasdaq and indicates that the market is currently closed with no trades. The content brie
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 04:12
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Tiziana Life Sciences Ltd – NASDAQ:TLSA
The article discusses the enterprise value to revenue forward for Tiziana Life Sciences Ltd, traded on NASDAQ under the ticker TLSA. It presents financial information for the company, accessible through TradingView. The content provides a snapshot of the company's market and fina
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 05 Jul 2026 08:40
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Tiziana Life Sciences Ltd – NASDAQ:TLSA
This article provides financial data for Tiziana Life Sciences Ltd (NASDAQ: TLSA), specifically focusing on its enterprise value to EBIT forward. The content appears to be a stub or an incomplete data presentation page from TradingView, lacking detailed analysis or narrative. It
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jul 2026 00:39
- Source
- TradingView
TradingView
Direct company coverage
Tiziana Life Sciences Ltd. Actuals & Estimates (DUS:0RP)
This article provides financial actuals and estimates for Tiziana Life Sciences Ltd. (DUS:0RP), covering income statement, balance sheet, and cash flow. It includes analyst forecasts, historical price data, earnings report dates, net income figures, dividend policy, and employee
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 12:09
- Source
- TradingView
TradingView
Direct company coverage
Tiziana Life Sciences Ltd. Actuals & Estimates (NASDAQ:TLSA)
This article provides financial actuals and estimates for Tiziana Life Sciences Ltd. (NASDAQ:TLSA), including its current stock price, historical performance, analyst forecasts, and company financials. It also answers frequently asked questions regarding its stock ticker, market
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 27 Jun 2026 00:40
- Source
- TradingView
TradingView
Direct company coverage
Tiziana Life Sciences Ltd. Actuals & Estimates (LSX:A3C5SS)
This article provides an overview of Tiziana Life Sciences Ltd. (A3C5SS) stock performance, financial actuals, and analyst estimates. It highlights the current stock price, recent declines, market capitalization, and upcoming earnings report. The piece also includes frequently as
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 09:39
- Source
- TradingView
Moomoo
Direct company coverage
Tiziana Life Sciences Doses Last Patient in Phase 2 Trial of Potential Multiple Sclerosis Treatment
Tiziana Life Sciences has completed dosing the last patient in its Phase 2 clinical trial for its potential multiple sclerosis treatment, milciclib. The study aims to evaluate milciclib's efficacy and safety in patients with progressive multiple sclerosis. This milestone marks a
- Tone
- Positive 69/100
- Event
- Market update
- Published
- 26 Jun 2026 07:10
- Source
- Moomoo
TradingView
Direct company coverage
TLSA Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Tiziana Life Sciences Ltd (TLSA) stock. According to one analyst, the 1-year price target is $9.01, with both the maximum and minimum estimates at this value. The article also covers current stock performance, historical highs
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 26 Jun 2026 06:11
- Source
- TradingView
Yahoo! Finance Canada
Direct company coverage
Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial
Tiziana Life Sciences has dosed the last patient in its Phase 2a clinical trial for intranasal foralumab to treat non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data from the study is anticipated in late Q3 or early Q4 2026, with results planned for presen
- Tone
- Positive 74/100
- Event
- Earnings
- Published
- 25 Jun 2026 17:09
- Source
- Yahoo! Finance Canada
GlobeNewswire
Direct company coverage
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 11:00
- Source
- GlobeNewswire
Via Ritzau
Direct company coverage
Tiziana Life Sciences Ltd.
Tiziana Life Sciences has announced the successful dosing of the last patient in its Phase 2a INFORM-MS clinical trial for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data from the study, which evaluates intranasal foralumab, a fully human anti-CD3 mono
- Tone
- Positive 74/100
- Event
- Market update
- Published
- 25 Jun 2026 11:10
- Source
- Via Ritzau
Stock Titan
Direct company coverage
Tiziana doses final INFORM-MS patient ahead of late-2026 data
Tiziana Life Sciences (Nasdaq: TLSA) has announced the successful dosing of the last patient in its Phase 2a INFORM-MS trial for intranasal foralumab, a treatment for non-active secondary progressive multiple sclerosis. Topline data from this randomized, double-blind, placebo-con
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 25 Jun 2026 11:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
Tiziana (Nasdaq: TLSA) completes enrollment in Phase 2a INFORM-MS study
Tiziana Life Sciences (Nasdaq: TLSA) has announced the completion of enrollment for its Phase 2a INFORM-MS trial, with the last patient dosed with intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This randomized, double-blind, placebo-contro
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 25 Jun 2026 11:10
- Source
- Stock Titan
TradingKey
Direct company coverage
Tiziana Life Sciences Ltd (TLSA) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Tiziana Life Sciences Ltd (TLSA), detailing analyst ratings and target prices. Based on one analyst, the stock has a "Buy" rating with a target price of USD 8.00, representing a significant upside. The report highlights current marke
- Tone
- Positive 70/100
- Event
- Earnings
- Published
- 18 Jun 2026 10:10
- Source
- TradingKey
TradingKey
Direct company coverage
Tiziana Life Sciences Ltd (TLSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Tiziana Life Sciences Ltd (TLSA), focusing on its stock performance, indicators, and moving averages. It highlights that critical support and resistance data have not yet been disclosed by the company. The analysis shows an overall 'S
- Tone
- Negative 30/100
- Event
- Market update
- Published
- 18 Jun 2026 10:10
- Source
- TradingKey
Stock Titan
Direct company coverage
Tiziana Life Sciences (TLSA) insider awarded 15,000 common shares
Tiziana Life Sciences Ltd. director Gabriele M. Cerrone was indirectly awarded 15,000 shares of common stock on June 12, 2026, at $1.11 per share through Panetta Partners Limited. This transaction increases his indirect holdings to 44,772,230 shares. The Form 4 filing indicates a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 10:41
- Source
- Stock Titan
The Globe and Mail
Direct company coverage
Tiziana Life Sciences Chair Boosts Stake as Foralumab Trials Advance
Tiziana Life Sciences' Executive Chairman, Gabriele Cerrone, has increased his stake in the company by purchasing 15,000 common shares for $1.11 each, bringing his total holding to 34.89%. This move demonstrates insider confidence as the company advances its intranasal foralumab
- Tone
- Positive 70/100
- Event
- Deals and strategy
- Published
- 17 Jun 2026 02:10
- Source
- The Globe and Mail
The Manila Times
Direct company coverage
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
Tiziana Life Sciences announced that its Executive Chairman and Founder, Gabriele Cerrone, through Panetta Partners Ltd, purchased an additional 15,000 common shares at $1.11 per share. This transaction increases his total holdings to 44,772,230 common shares, representing 34.89%
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 15 Jun 2026 13:10
- Source
- The Manila Times
MT Newswires
Direct company coverage
Tiziana Life Sciences Executive Chairman Gabriele Cerrone Increases Holdings
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 15 Jun 2026 11:55
- Source
- MT Newswires
Stock Titan
Direct company coverage
Founder now owns 34.89% of Tiziana Life Sciences after 15K-share buy
Tiziana Life Sciences Executive Chairman and founder Gabriele Cerrone increased his stake in the company by purchasing 15,000 common shares at $1.11 each. This transaction, made through Panetta Partners, brings his total holding to 44,772,230 shares, representing 34.89% of the co
- Tone
- Positive 72/100
- Event
- Deals and strategy
- Published
- 15 Jun 2026 11:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
Tiziana (NASDAQ: TLSA) chair lifts stake with 15,000-share purchase
Tiziana Life Sciences Ltd's Executive Chairman and Founder, Gabriele Cerrone, has increased his stake by purchasing 15,000 common shares at $1.11 each, bringing his total holding to 34.89% of the company's issued share capital. The company is developing intranasal foralumab, a fu
- Tone
- Positive 71/100
- Event
- Deals and strategy
- Published
- 15 Jun 2026 11:09
- Source
- Stock Titan
Proactive financial news
Direct company coverage
Tiziana executive chairman increases stake
Tiziana Life Sciences Ltd's Executive Chairman and Founder, Gabriele Cerrone, has increased his ownership stake in the company through Panetta Partners Ltd. Cerrone purchased 15,000 common shares at $1.11 each, bringing his total holdings to 44.77 million shares, which represents
- Tone
- Positive 71/100
- Event
- Deals and strategy
- Published
- 15 Jun 2026 08:09
- Source
- Proactive financial news
Simply Wall Street
Direct company coverage
Tiziana Life Sciences (Nasdaq:TLSA) - Stock Analysis
Tiziana Life Sciences (Nasdaq:TLSA) is a biotechnology company focused on developing therapies for neurodegenerative and lung diseases. The company's lead product candidate, Foralumab, an intranasal anti-CD3 monoclonal antibody, is currently undergoing clinical trials for non-act
- Tone
- Positive 76/100
- Event
- Market update
- Published
- 31 May 2026 18:39
- Source
- Simply Wall Street
Market source
Direct company coverage
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
Tiziana Life Sciences announced it will present at the Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026. CEO Ivor Elrifi and COO/CFO Keeren Shah will provide updates on the company's clinical programs and strategic direction. The presentation will high
- Tone
- Positive 73/100
- Event
- Market update
- Published
- 31 May 2026 08:39
- Source
- Market source
Finviz
Direct company coverage
TLSA - Tiziana Life Sciences Ltd Stock Price and Quote
This page provides a comprehensive overview of Tiziana Life Sciences Ltd (TLSA) stock, including its latest trading data, financial metrics, and recent news. The company is a clinical-stage biotechnology firm focused on therapies for neurodegenerative and lung diseases, with a pi
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 30 May 2026 18:40
- Source
- Finviz
Stock Titan
Direct company coverage
Biotech Tiziana to brief investors on clinical updates at Jefferies event
Tiziana Life Sciences (Nasdaq: TLSA) announced it will present at the Jefferies Global Healthcare Conference on June 4, 2026. CEO Ivor Elrifi and COO/CFO Keeren Shah will provide corporate and clinical updates, including advancements for their lead candidate, intranasal foralumab
- Tone
- Positive 64/100
- Event
- Market update
- Published
- 28 May 2026 11:08
- Source
- Stock Titan
Stock Titan
Direct company coverage
[6-K] Tiziana Life Sciences Ltd Current Report (Foreign Issuer) | TLSA SEC Filing - Form 6-K
Tiziana Life Sciences (NASDAQ: TLSA) announced it will present at the Jefferies Healthcare Conference in New York City on June 4, 2026. CEO Ivor Elrifi and COO/CFO Keeren Shah will provide a corporate presentation highlighting recent clinical and corporate developments, particula
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 11:08
- Source
- Stock Titan